| アブストラクト | Ischemic heart disease is the primary cause of death worldwide. The pathophysiological process of cardiovascular diseases is linked to atheromatous plaque formation, while plaque rupture releases thrombogenic elements, which lead to activation of platelets, blood clotting and formation of thrombi. Platelet inhibitors are used to prevent thrombosis. The present systematic review discusses the efficacy of prasugrel in terms of platelet inhibition potential and clinical prevention of cardiovascular outcomes. The balance between reduction of ischemic events as a measure of drug efficacy and the risk of bleeding is reviewed. Other adverse events observed in patients treated with this platelet inhibitor are discussed, including hematological complications, and cutaneous and hepatic idiosyncratic reactions. The complex relationship between prasugrel use and cancer promotion is also described. |
|---|
| 組織名 | In Vitro Drug Safety and Biotechnology, Toronto, ON, Canada; Department of;Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto,;ON, Canada.;In Vitro Drug Safety and Biotechnology, Toronto, ON, Canada; Faculty of Pharmacy,;University Paul Sabatier, Toulouse, France.;ON, Canada. Electronic address: manuela.neuman@utoronto.ca. |
|---|
